Compare BridgeBio Pharma Inc (BBIO) vs KeyCorp (KEY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs KeyCorp — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.36B), while KeyCorp trades at $22.7 (market cap $24.32B). The key difference: KeyCorp is the larger of the two by market cap, and KeyCorp pays a 3.61% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | KEY | |
|---|---|---|
Market Cap | $16.36B | $24.32B |
Sector | Health | Financials |
52-Week High | $90.17 | $23.99 |
52-Week Low | $47.29 | $16.78 |
Enterprise Value | $18.14B | — |
Dividend Yield | — | 3.61% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →
